Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Aadi Bioscience initiates rolling submission of NDA to FDA for nab-sirolimus for advanced malignant PEComa

pharmaceutical-business-reviewJuly 01, 2020

Tag: Aadi Bioscience , nab-sirolimus , PEComa

PharmaSources Customer Service